MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity’s patent exclusivity in the U.S. into 2042. “This dosing regimen patent reflects our commitment to enhancing our intellec

Adding a fourth certified facility within its global network increases operational capacity to better serve international medical markets NASDAQ | TSX: ACB EDMONTON, AB, July 14, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that its dedicated distribution centre located in Brampton, Ontario, has received European Union Good Manufacturing Practice ("EU-GMP") certification, increasing the compa

MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first autologous cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics® (NASDAQ: ABEO). Throughout clinical development, Simple Western enabled precise identification and quantification of Collagen VII,

First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026 MCO-010 BLA for retinitis pigmentosa is eligible for priority review based on fast-track designation If approved, MCO-010 has the potential to be the standard of care for retinitis pigmentosa, delivered via a one-time, in-office intravitreal injection with the ability to restore vision in patients with severe vision loss regardless of their underlying genetic mutation DALLAS, July 14, 2025

DETROIT, July 14, 2025 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, cancer centers, and other organizations nationwide recognize July as Sarcoma Awareness Month. Sarcomas are rare tumors that make up about 1% of all adult cancers and 15% of childhood cancers. In 2025, over 13,500 new cases of sarcoma will be diagnosed in the U.S. Karmanos offers an expert team dedicated to diagnosing and treating these uncommon tumors. Continue Reading Karmanos Cancer Institute recognizes July as S

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), proposes to offer ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Share

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 /PRNewswire/ -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing inves

Takeda’s oral orexin agonist has cleared a pair of Phase 3 trials in a sleep disorder, marking the first late-stage win for a drug class that Wall Street analysts say has multi-billion dollar potential. Oveporexton, as Takeda’s drug is known, achieved a “statistically significant improvement” over placebo on all endpoints in the FirstLight and RadiantLight studies, according to a Monday release . The trials enrolled more than 100 patients each with narcolepsy type 1, a chronic disorder that caus

AstraZeneca’s pill baxdrostat looks likely to win approval in uncontrolled and treatment-resistant hypertension after succeeding in its pivotal trial. And the results validate the company’s 2023 buyout of CinCor Pharma, which originated the drug, for a $1.3 billion upfront. The UK pharma said Monday that patients who took baxdrostat once-daily for three months had a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure, compared with those given pla